Idamycin PFS (IDARUBICIN HYDROCHLORIDE)
Idamycin PFS (IDARUBICIN HYDROCHLORIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Idamycin PFS; Generic name: IDARUBICIN HYDROCHLORIDE; Manufacturer: Pfizer Laboratories Div Pfizer Inc.
| Brand name | Idamycin PFS |
|---|---|
| Generic name | IDARUBICIN HYDROCHLORIDE |
| Manufacturer | Pfizer Laboratories Div Pfizer Inc |
| Used for | 1 INDICATIONS AND USAGE IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Induction Therapy • 12 mg/m 2 intravenously over 10 to 15 minutes on days 1, 2, and 3 of induction in combination with cytarabine 100 mg/m 2 by continuous intravenous infusion daily for 7 days or cytarabine 25 mg/m 2 intravenous bolus followed by cytarabine 200 mg/m 2 continuous intravenous infusion daily for 5 days. (2.1) • IDAMYCIN PFS can be given as part of a combination regimen with other chemotherapeutic drugs. (2.1) • Renal Impairment: Assess renal function pri |
| Warnings | WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, and EXTRAVASATION AND TISSUE NECROSIS • Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment [see Warnings and Precautions |
| Active ingredient(s) | IDARUBICIN HYDROCHLORIDE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3 |